Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3853 participants.

Also called NCT07173855

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,853 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07173855
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07173855. Randomized; no masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
Acronym
MAGNOLIA
Condition
Critical Illness
Intervention (Drug)
Magnesium sulfate administration
Intervention (Drug)
Magnesium oxide
Intervention (Drug)
Magnesium glucoheptonate
Lead sponsor
Scarborough General Hospital (class: other)
Collaborator
Scarborough Health Network (class: other)
Collaborator
Lakeridge Health Corporation (class: other)

Record details

Record id
cardio:ct-nct07173855
Content hash
a7553aef0616a41088f63ee846c166f2fac695682fa01ad7c5be362f6e3ac728